1,539
Views
10
CrossRef citations to date
0
Altmetric
Articles

RETRACTED ARTICLE: Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study

, , , , , , , & show all
Pages 1708-1718 | Received 24 Jul 2017, Accepted 10 Oct 2017, Published online: 25 Oct 2017
 

Abstract

We, the authors, Editors and Publisher of the journal Artificial Cells, Nanomedicine, and Biotechnology, have retracted the following article:

Ling Rong, Shuping Zhou, Xinkuang Liu, Amin Li, Tao Jing, Xueke Liu, Yinci Zhang, Shiyu Cai & Xiaolong Tang (2018) Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro and in vivo study. Artificial Cells, Nanomedicine, and Biotechnology, 46:8, 1708–1718, DOI: 10.1080/21691401.2017.1391821

Since publication, the authors noticed errors in Figures 7 b and 5c, which directly impacts the reported results and conclusions. The authors alerted the issue to the Editor and Publisher and all have agreed to retract the article to ensure correction of the scholarly record. The authors plan to re-run the experiment and verify their data.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as ‘Retracted’.

View retraction statement:
Statement of Retraction

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.